International Myeloma Society
Healthcare Professional Disclaimer
All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Multiple Myeloma Hub Overview
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Main Sections
Types
- High-risk
- MGUS
- Newly diagnosed multiple myeloma
- Plasma cell dyscrasias
- Plasma cell leukemia
- Relapsed/refractory multiple myeloma
- Smoldering multiple myeloma
- Translocation (11;14)
Therapeutics
- Alnuctamab
- Anitocabtagene autoleucel
- Antibody therapy
- Auto-HSCT
- BCMA CAR-T
- Belantamab mafodotin
- Bortezomib
- CAR therapy
- Carfilzomib
- Cellular therapy
- Cevostamab
- Ciltacabtagene autoleucel
- Cyclophosphamide
- Daratumumab
- Dexamethasone
- Elotuzumab
- Elranatamab
- Equecabtagene Autoleucel
- Etentamig
- HDP-101
- Iberdomide
- Idecabtagene vicleucel
- Immune modulators
- Isatuximab
- ISB 2001
- Ixazomib
- Lenalidomide
- Linvoseltamab
- Mezigdomide
- P-BCMA-ALLO1
- Pomalidomide
- PROTACS
- Proteasome inhibitors
- Selinexor
- T-cell engagers
- Talquetamab
- Targeted protein degraders
- Teclistamab
- Thalidomide
- Venetoclax
Congresses
- ASCO 2022
- ASH 2024
- ASH 2025
- EHA 2025
- IMS 2022
- IMS 2023
- IMS 2024
- IMS 2025
- IMS Workshop 2023
- IMS Workshop 2024
Trials
- ATLAS
- AURIGA
- BENEFIT
- CA057-003
- CAMMA-1
- CARTITUDE-1
- CARTITUDE-2
- CARTITUDE-4
- CASSIOPEIA
- CC-92480-MM-001
- CC-92480-MM-002
- CEPHEUS
- DREAMM-8
- DREAMM-9
- EMN26
- EXCALIBER-Maintenance
- EXCALIBER-RRMM
- FUMANBA-1
- GEM-BELA-VRd
- GEM-IBER
- DARAX
- GMMG-CONCEPT
- I2D
- IFM2021_03
- ICONIK
- EMAI
- ROZIRAKLI
- KarMMa
- KarMMa-9
- LINKER-MM1
- MagnetisMM-30
- MagnetisMM-6
- MAIA
- MajesTEC-5
- MELT-MM
- OPTIMISM
- MPERSEUS
- RedirecTT-1
- STOMPS
- SUCCESSOR-1
- SUCCESSOR-2
Expert Opinions
- Irene Ghobrial
- Jonathan L. Kaufman
- Krina Patel
- María-Victoria Mateos
- Maximilian Merz
- Mohamad Mohty
- Roman Hájek
Educational Resources
- Focused reviews
- Spotlights
Featured Articles
- Targeting cereblon for the treatment of MM: Rationale and latest data
- CAMMA 1: Phase 1B dose-expansion results for cevostamab Pd in RRMM
- Outcomes with novel CELMoD agents for MM
- CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT
- IMS 2025 | Other plasma cell dyscrasias
- IMS 2025 | Relapsed/refractory multiple myeloma
- IMS 2025 | Newly diagnosed multiple myeloma
- IberDd for transplant-ineligible patients with NDMM: Results from the phase I/II CC-220-MM-001 trial
- Phase I trial on the efficacy and safety of P-BCMA-ALLO1 CAR T-cell therapy in RRMM
- GEM-BELA-VRd: Belantamab mafodotin in combination with VRd for transplant-eligible NDMM
- #IMS2024: Relapsed/refractory multiple myeloma
- #IMS2024: Newly diagnosed multiple myeloma
- Novel bispecific antibodies in MM: characteristics and latest data
- Dual antigen targeting immunotherapies in MM
- What is the rationale for T-cell therapies in the treatment of smoldering MM?
- Antigen escape as a mechanism of resistance to T-cell-engaging therapies in multiple myeloma
- The impact of physical activity on functional performance in multiple myeloma
- For a triple-class refractory patient entering 4L therapy, how would you sequence BCMAxCD3 and GPRC5DxCD3 bispecifics?
- IKEMA trial: Isa-Kd versus Kd for RRMM – final overall survival analysis
- What is the rationale for combination venetoclax+Kd treatment in patients with t(11;14) RRMM?
Conclusion
This article covers essential updates on multiple myeloma focusing on the types, therapeutics, congresses, trials, expert opinions, and educational resources.